Zhichong Pharmaceuticals has recently made an announcement that it has successfully raised tens of millions of yuan in its Series A1 funding round, with Tianhui Capital taking the lead. The capital raised will be predominantly allocated to expedite the clinical development of its core drug candidates, enhance its end-to-end AI-driven drug discovery platform, and broaden its pipeline strategy in therapeutic areas such as anti-infectives, chronic diseases, central nervous system (CNS) disorders, and anti-aging. As the first company in China to fully integrate generative AI technology into the development of innovative pet medications, Zhichong Pharmaceuticals positions itself as a Techbio enterprise. Leveraging its proprietary dual-engine platform for small and large molecules, along with real-world scenarios in pet medication, the company has established a cost-effective, short-cycle true validation closed-loop system. This system allows for quicker validation fields, shorter observation periods, and a well-proven translational pathway, enabling the accumulation of exclusive closed-loop data. By harnessing end-to-end AI to tackle generation challenges and comparative medicine to address translational hurdles, the company achieves a dual-wheel drive in terms of both speed and depth. Currently, Zhichong Pharmaceuticals boasts over six drug candidates with the potential to be First-in-Class (FIC) or Best-in-Class (BIC). Tianhui Capital is bullish on the development prospects of Zhichong Pharmaceuticals' composite team and the pet medication sector. Additionally, it recognizes the long-term value of extending the comparative medicine approach to human applications, particularly in areas such as anti-aging and CNS disorders, and will continue to offer post-investment support.